株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アジソン病(原発性または慢性副腎皮質機能低下症):世界の治験動向

Addison's Disease (Primary or Chronic Adrenal Insufficiency) Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 301446
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
アジソン病(原発性または慢性副腎皮質機能低下症):世界の治験動向 Addison's Disease (Primary or Chronic Adrenal Insufficiency) Global Clinical Trials Review, H1, 2017
出版日: 2017年03月15日 ページ情報: 英文 49 Pages
概要

当レポートでは、アジソン病の治療薬に関する治験について調査分析し、治験数および被験者数、段階別・状況別の状況、有望企業、開発中の治療薬の情報、治験プロファイルなどを提供しています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数

G7諸国での治験件数:ホルモン障害治療薬の治験におけるアジソン病 (原発性または慢性副腎皮質機能低下症) の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

アジソン病 (原発性または慢性副腎皮質機能低下症) 治療薬の治験に携わっている主要企業

有望な薬剤

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

GlobalData's clinical trial report, "Addison's Disease (Primary or Chronic Adrenal Insufficiency) Global Clinical Trials Review, H1, 2017" provides an overview of Addison's Disease (Primary or Chronic Adrenal Insufficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Addison's Disease (Primary or Chronic Adrenal Insufficiency). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Clinical Trials by G7 Countries: Proportion of Addison's Disease (Primary or Chronic Adrenal Insufficiency) to Hormonal Disorders Clinical Trials 13
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by Phase 17
  • In Progress Trials by Phase 18
  • Clinical Trials by Trial Status 19
  • Clinical Trials by End Point Status 20
  • Subjects Recruited Over a Period of Time 21
  • Clinical Trials by Sponsor Type 22
  • Prominent Sponsors 23
  • Top Companies Participating in Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials 24
  • Prominent Drugs 25
  • Clinical Trial Profile Snapshots 26

Appendix 46

  • Abbreviations 46
  • Definitions 46
  • Research Methodology 47
  • Secondary Research 48
  • About GlobalData 48
  • Contact Us 48
  • Disclaimer 49
  • Source 49

List of Tables

List of Tables

  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 10
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Proportion of Addison's Disease (Primary or Chronic Adrenal Insufficiency) to Hormonal Disorders Clinical Trials, G7 Countries (%), 2017* 14
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials by Phase, 2017* 17
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 18
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 19
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 20
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 21
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 22
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 23
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 24
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 25

List of Figures

List of Figures

  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
  • Proportion of Addison's Disease (Primary or Chronic Adrenal Insufficiency) to Hormonal Disorders Clinical Trials, G7 Countries (%), 2017* 13
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 17
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 18
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 19
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 20
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 21
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 22
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 23
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 24
  • Addison's Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 25
  • GlobalData Methodology 47
Back to Top